What is the recommended Pramlintide (Symlin) dosage?

Pramlintide (Symlin) dosing varies by experience level. Beginners typically start at 15mcg 3x daily, moderate users at 60mcg 2x daily, and aggressive protocols use 120mcg 3x daily.

How do you reconstitute Pramlintide (Symlin)?

Pramlintide (Symlin) comes as a pre-filled device — no reconstitution needed.

What is the half-life of Pramlintide (Symlin)?

The half-life of Pramlintide (Symlin) is ~48 minutes. This determines how frequently you need to dose for consistent blood levels.

Pramlintide (Symlin)

Weight LossInjectionFDA ApprovedGrade B~48 minutes half-life

Amylin AnalogFDA-ApprovedDiabetesPostprandial GlucoseWeight ManagementPre-Meal Injection

Benefits

Reduces postprandial glucose spikes by 3.4-5 mmol/L beyond what insulin alone achieves

Promotes modest weight loss (0.5-1.6 kg) instead of the weight gain typical with insulin

Slows gastric emptying for more gradual glucose absorption after meals

Suppresses inappropriate postprandial glucagon secretion

Increases satiety and reduces caloric intake at meals

HbA1c improvement of 0.2-0.6% as add-on to insulin therapy

FDA-approved with over 20 years of post-marketing safety data

Half-Life

~48 minutes

Route

Injection

Frequency

3x Daily

Vial Sizes

1mg

BAC Water

Pre-filled

Safety Grade

Grade B

Open Pramlintide (Symlin) Dosage Calculator

Calculate exact syringe units for your vial and dose

About Pramlintide (Symlin)

Pramlintide (brand name Symlin) is an FDA-approved synthetic analog of human amylin, a 37-amino acid hormone co-secreted with insulin by pancreatic beta cells after meals. In type 1 diabetes, amylin production is essentially absent; in type 2 diabetes, it is significantly impaired. Pramlintide replaces this missing hormone. Approved in March 2005, pramlintide is the only amylin analog on the market. It works through three mechanisms that insulin cannot address: it slows gastric emptying so glucose enters the bloodstream more gradually, it suppresses inappropriate postprandial glucagon secretion from alpha cells, and it promotes satiety through central receptors in the area postrema. The net effect is significantly lower post-meal glucose spikes — something that even optimized insulin regimens struggle to achieve alone. In clinical trials, adding pramlintide to insulin therapy reduced HbA1c by 0.2-0.6% and postprandial glucose by 3.4-5 mmol/L. Patients also lost 0.5-1.6 kg of body weight, which is notable because insulin therapy typically causes weight gain. The weight loss effect, while modest, comes from reduced food intake driven by increased satiety signaling. Pramlintide carries a black box warning for severe hypoglycemia, particularly in type 1 diabetes patients. This risk is highest during the first 4 weeks and is managed by cutting the mealtime insulin dose by 50% when initiating pramlintide. It requires three daily injections before major meals, which limits adherence for some patients. Next-generation amylin analogs like cagrilintide aim to solve this with weekly dosing.

Who Should Consider Pramlintide (Symlin)

Adults with type 1 diabetes who have not achieved glycemic targets despite optimized insulin therapy
Adults with type 2 diabetes using mealtime insulin who need better postprandial glucose control
Insulin-using diabetics experiencing weight gain who want a weight-neutral or weight-reducing adjunct
Patients with high postprandial glucose excursions despite pre-meal insulin dosing
Adults willing to add pre-meal injections for tighter glucose control

How Pramlintide (Symlin) Works

Pramlintide is a synthetic analog of human amylin with three proline substitutions at positions 25, 28, and 29 that prevent the aggregation and amyloid formation seen with native amylin. It binds to amylin receptors (heterodimers of the calcitonin receptor with receptor activity-modifying proteins RAMP1, RAMP2, or RAMP3) in the area postrema and hypothalamus. Activation of these receptors triggers three effects that complement insulin: (1) slowing gastric emptying through vagal inhibition, extending the time glucose takes to reach the bloodstream after a meal; (2) suppressing postprandial glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output after eating; and (3) promoting satiety through central nervous system signaling, which reduces food intake. These three actions together flatten the postprandial glucose curve in a way that insulin alone cannot achieve. The glucagon suppression is meal-specific — it does not impair the counter-regulatory glucagon response to hypoglycemia.

What to Expect

Days 1-7

Starting at the lowest dose (15 mcg for T1D, 60 mcg for T2D). Nausea is most common during this period. Mealtime insulin has been cut by 50%. Blood glucose may run slightly higher as the insulin-pramlintide balance is established. Frequent monitoring required.

Weeks 1-4

Titrating upward every 3-7 days as tolerated. Post-meal glucose spikes begin to flatten noticeably. Nausea typically peaks and then starts to fade. This is the highest-risk window for hypoglycemia — watch for symptoms within 3 hours after injection. Insulin doses are being fine-tuned.

Weeks 5-12

Reaching maintenance dose (30-60 mcg for T1D, 120 mcg for T2D). Postprandial glucose reductions of 3-5 mmol/L become consistent. GI side effects have largely resolved. Mild weight loss of 0.5-1 kg may be noticeable. HbA1c starts to trend downward.

Months 3-6

Full glycemic benefit realized. HbA1c reduced by 0.2-0.6% from baseline. Weight stable or slightly decreased compared to insulin-only regimen. Postprandial glucose control is predictable. Insulin doses have been re-optimized.

Months 6-12+

Long-term maintenance. Glycemic improvements sustained. Weight remains stable or slightly below pre-pramlintide levels. Continued adherence to pre-meal timing is necessary for effectiveness.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	15mcg	3x Daily
Moderate	60mcg	2x Daily
Aggressive	120mcg	3x Daily

Note: FDA-approved amylin analog (brand: Symlin). Injected subcutaneously before major meals. Type 1: titrate 15 mcg to 60 mcg. Type 2: titrate 60 mcg to 120 mcg. Always used as adjunct to mealtime insulin — never as a standalone. Reduce insulin dose by 50% when starting to prevent hypoglycemia.

How to Inject Pramlintide (Symlin)

Inject subcutaneously into the abdomen or thigh immediately before major meals (15 minutes or less). Do not inject into the same site as insulin — use a separate injection site at least 2 inches away. Type 1 diabetes: start at 15 mcg before meals, increase by 15 mcg increments every 3-7 days to a target of 30-60 mcg as tolerated. Type 2 diabetes: start at 60 mcg before meals, increase to 120 mcg after 3-7 days if tolerated. Always reduce mealtime insulin by 50% when initiating pramlintide. Monitor blood glucose before and after meals, especially during the first 4 weeks.

Cycling Protocol

On Period

52 weeks

Off Period

0 weeks

Continuous therapy — pramlintide is designed for ongoing daily use alongside insulin. There is no cycling protocol. Stopping pramlintide requires re-adjusting insulin doses upward to compensate for the loss of glucagon suppression and gastric emptying effects.

Pharmacokinetics

Half-Life

48min

Bioavailability

SC: ~30-40%

Tmax

~20 minutes (SC)

Data Confidence

high

Source: FDA prescribing information: approximately 48 minutes in healthy subjects (SC administration)

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

BLACK BOX WARNING: Pramlintide used with insulin carries a risk of severe hypoglycemia, particularly in type 1 diabetes. This risk is greatest within the first 4 weeks of treatment. Severe hypoglycemia can occur within 3 hours of injection. Mealtime insulin doses must be reduced by 50% when starting pramlintide, and blood glucose must be monitored frequently. Nausea is the most common side effect, affecting 10-59% of patients across trials — it is usually mild to moderate and decreases over 2-8 weeks. Vomiting occurs in 6-14% of patients. Reduced appetite (2-9%) is expected given the mechanism. Headache, abdominal pain, and fatigue are reported at low rates. Injection site reactions (redness, swelling, bruising) occur occasionally. Pramlintide should not be used in patients with gastroparesis, as it further delays gastric emptying.

Contraindications

Confirmed gastroparesis or significant gastrointestinal motility disorder — pramlintide further delays gastric emptying
Hypoglycemia unawareness — the combined hypoglycemia risk with insulin is too high
Known hypersensitivity to pramlintide, metacresol, or any excipient in Symlin
HbA1c > 9% or recurrent severe hypoglycemia in the past 6 months — glucose instability makes dose titration unsafe
Poor compliance with insulin regimen, glucose monitoring, or physician follow-up
Pregnancy or breastfeeding — no adequate safety data; amylin receptor effects on fetal development not studied
Pediatric patients under 18 — not approved for use in children
Concurrent use of medications that slow GI motility (e.g., anticholinergics, alpha-glucosidase inhibitors)

Drug Interactions

Mealtime insulin (rapid-acting) — MUST reduce dose by 50% when starting pramlintide; severe hypoglycemia risk
Sulfonylureas and meglitinides — additive hypoglycemia risk; dose adjustment may be needed
Alpha-glucosidase inhibitors (acarbose, miglitol) — both delay carbohydrate absorption; combined use not recommended
Anticholinergic agents — additive gastric emptying delay; avoid concurrent use
Oral medications requiring rapid GI absorption — pramlintide slows gastric emptying and may delay absorption of concurrently administered oral drugs; take oral medications 1 hour before or 2 hours after pramlintide
GLP-1 receptor agonists (semaglutide, liraglutide) — overlapping GI slowing effects; combined use not studied and may increase nausea and hypoglycemia risk